On one of the last days of 2020 I added a position in Bristol-Myers Squibb (ticker: BMY). I wanted to strengthen the healthcare part of my portfolio. I only held JNJ and Baxter and wanted to diversify a bit further by adding a big pharmaceutical company to my roster.
I hesitated between purchasing shares of Bristol-Meyers, Pfizer or Abbvie. I compared their yields, valuation and other financial indicators but the differences were actually rather limited. I find it difficult to judge how their pipelines look and what I can expect in terms of future revenue growth between these companies. In the end, I went with BMY because of their slightly better valuation. Their ex-dividend date is actually today (not really a coincidence) so I expect to receive my first dividend payment February 1.
I added 22 shares for about $61,60 per share. This purchase will add roughly € 35 to my annual dividend income stream which stands at around € 1.840 pre-tax.
What do you think of my purchase?
No comments:
Post a Comment